Home Tags XpressCF+

Tag: XpressCF+

Preclinical Data Suggests Synergy between STRO-002 and Immune Checkpoint Inhibitors, Resulting...

Data presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020 of Sutro Biopharma's folate receptor...

SutroVax Closes U.S. $ 110 million Series D financing to Advance...

SutroVax, a next-generation vaccine company, has closed a $110 million Series D preferred stock financing, co-led by new investors RA Capital Management and Janus...
Featured Image: Boston Public Garden; Boston, MA. Courtesy: © 2017 Fotolia. Used with permission.

Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002...

Initial safety data of STRO-002 shows potent anti-tumor activity in preclinical endometrial cancer patient-derived xenograft (PDX) models were presented at the AACR-NCI-EORTC.FRα is overexpressed...

Sutro Biopharma to Receive Milestone Payment from Merck KGaA for Bispecific...

Sutro Biopharma has achieved a milestone under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany, in the United...

Sutro Confirms IND for Second Cell-Free ADC Targeting Anti-Folate Receptor-α for...

Sutro Biopharma confirmed that the U.S. Food and Drug Administration (FDA) has concluded their 30-day review of the Investigational New Drug (IND) application for...

A New Generation of Precisely Engineered CD74-Targeting ADCs Receive Orphan Drug...

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for STRO-001 for the treatment of multiple myeloma (MM).In the United States,...

First Clinical Trial of STRO-001 Targeting CD74 to Treat Lymphoma and...

Researchers have begun dosing patients in its initial clinical trial of a new generation of precisely engineered - first-in-class - antibody-drug conjugate, or ADC,...

Promising Preclinical Results Show Antibody Effectively Targets CD74 in Lymphoma and...

Two studies presented at the annual meeting of the American Society of Hematology (ASH), held December 9 - 12, 2017, showed frequent expression of...